Phase 2b program with sonlicromanol in patients with mitochondrial disease due to m.3243A>G mutation - Top-Institutions - MDSpire

Phase 2b program with sonlicromanol in patients with mitochondrial disease due to m.3243A>G mutation

  • By

  • Jan Smeitink

  • Just van Es

  • Brigitte Bosman

  • Mirian C H Janssen

  • Thomas Klopstock

  • Grainne Gorman

  • John Vissing

  • Gerrit Ruiterkamp

  • Chris J Edgar

  • Evertine J Abbink

  • Rob van Maanen

  • Oksana Pogoryelova

  • Claudia Stendel

  • Almut Bischoff

  • Ivan Karin

  • Mahtab Munshi

  • Anne Kümmel

  • Lydia Burgert

  • Christianne Verhaak

  • Herma Renkema

  • November 6, 2024

  • 0 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    Mitochondrial Medicine Center, Massachusetts General Hospital
    Mitochondrial Medicine Center, Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Mitochondrial Medicine
    • Neurology
    • Genetics

  • #2

    The Mitochondrial Disease Program, Children's Hospital of Philadelphia
    The Mitochondrial Disease Program, Children's Hospital of Philadelphia

    Philadelphia, PA

    Key Differentiators

    • Pediatric Mitochondrial Medicine
    • Neurology
    • Metabolic Disorders

  • #3

    Newcastle Mitochondrial Research Group, Newcastle University
    Newcastle Mitochondrial Research Group, Newcastle University

    Newcastle upon Tyne, UK

    Key Differentiators

    • Mitochondrial Genetics
    • Neurology
    • Clinical Trials

  • #4

    Center for Mitochondrial and Epigenomic Medicine, Children's Hospital of Philadelphia
    Center for Mitochondrial and Epigenomic Medicine, Children's Hospital of Philadelphia

    Philadelphia, PA

    Key Differentiators

    • Mitochondrial Medicine
    • Epigenomics
    • Clinical Research

Original Source(s)

Phase 2b program with sonlicromanol in patients with mitochondrial disease due to m.3243A>G mutation

  • by Jan Smeitink, Just van Es, Brigitte Bosman, Mirian C H Janssen, Thomas Klopstock, Grainne Gorman, John Vissing, Gerrit Ruiterkamp, Chris J Edgar, Evertine J Abbink, Rob van Maanen, Oksana Pogoryelova, Claudia Stendel, Almut Bischoff, Ivan Karin, Mahtab Munshi, Anne Kümmel, Lydia Burgert, Christianne Verhaak, Herma Renkema

  • November 6, 2024

Related Content

Association between neurodegenerative plasma biomarkers and geriatric depression in older adults with and without clinical dementia in Kinshasa, Democratic Republic of the Congo

Impact of Occupational Therapy on Upper Limb Function and Rehabilitation Results Following Stroke: A Systematic Review and Meta-Analysis

Oral Glutamatergic Augmentation for Trauma-Related Disorders with Fluoxetine- / Bupropion-Potentiated Dextromethorphan ± Piracetam: A Four-Patient Case Series